Associated tags: Patient, Cell, Transplant, Vaccine, Pelvic floor dysfunction, Biotechnology, Pharmaceutical industry, Kidney, Dentistry, Research, Gene editing
Locations: UNITED STATES, NORTH AMERICA, JAPAN, ASIA PACIFIC, MASSACHUSETTS
Research,
Other Health,
General Health,
Oncology,
Hospitals,
Genetics,
Surgery,
Clinical Trials,
Science,
Biotechnology,
FDA,
Health,
Other Science,
Pelvic floor dysfunction,
MGH,
Kidney disease,
Gene,
Organization,
Survival,
Massachusetts General Hospital,
Transplant,
Inflammation,
Immunosuppression,
Kidney failure,
Mortality,
Coagulation,
Hope,
Doctor of Philosophy,
Expanded access,
Quality of life,
Genome,
Transgene,
Hospital,
Kidney,
Dialysis,
CD40L,
Courage,
Kidney transplantation,
Medicine,
Dentistry eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.
Key Points:
- eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.
- Following the procedure, the patient is in good condition and recovering well at MGH.
- Yet the demand for organs far outpaces supply, with more than 90,000 individuals on the kidney waitlist and approximately 25,000 kidney transplants performed each year.
- Decades of progress in cross-species transplantation, accelerated by the advancement of modern genome editing tools and next-generation sequencing, have enabled eGenesis to progress genetically engineered organs to the clinical setting.
Retrieved on:
Tuesday, February 13, 2024
Health Technology,
Other Health,
Technology,
Stem Cells,
Pharmaceutical,
Surgery,
Medical Devices,
Genetics,
Clinical Trials,
Biotechnology,
Science,
Software,
Veterinary,
Other Science,
Research,
Health,
Meiji University,
Embryology,
Cell,
Doctor of Philosophy,
Coagulation,
Inflammation,
Quality of life,
Pelvic floor dysfunction,
Transgene,
Transplant,
Genome,
Patient,
Gene,
Kidney,
Mortality,
Tissue,
Vaccine eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.
Key Points:
- eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.
- As part of a collaboration between the two companies, genetically engineered porcine cells developed by eGenesis were provided to PorMedTec for production using the somatic cell nuclear transfer, or cloning, process.
- eGenesis and PorMedTec plan to jointly advance the development of genetically engineered organs in Japan to address the massive unmet need in the country, with an initial focus on kidney transplant.
- “Cloning technology will enable the use of an alternative organ supply using genetically engineered porcine donors.
Retrieved on:
Thursday, January 18, 2024
Other Health,
Other Science,
Pharmaceutical,
Research,
Software,
Medical Devices,
Hospitals,
Genetics,
Data Management,
Science,
Technology,
Veterinary,
Clinical Trials,
General Health,
FDA,
Biotechnology,
Surgery,
Health,
Mortality,
Hope,
Family,
Patient,
Coagulation,
Liver failure,
Multimedia,
ELC,
MFS,
Pelvic floor dysfunction,
Gift,
Gene,
University,
Drug discovery,
Risk,
Perfusion,
Transgene,
IND,
Food,
Pressure,
Liver,
Inflammation,
Genome,
Organization,
CPTC,
Bile,
Cell,
Trial of the century,
Dietary supplement The perfusion was performed using the eGenesis liver, EGEN-5784, connected to the OrganOx extracorporeal liver cross-circulation (ELC) device to enable circulation of the donor’s blood through the porcine liver.
Key Points:
- The perfusion was performed using the eGenesis liver, EGEN-5784, connected to the OrganOx extracorporeal liver cross-circulation (ELC) device to enable circulation of the donor’s blood through the porcine liver.
- The efficacy of existing liver support options is limited, and patients in liver failure face a high risk of mortality.
- For some patients, utilizing a human-compatible, genetically engineered porcine whole liver to support the function of a patient’s decompensated liver may provide time for the recovery of the patient’s native liver or time to obtain a liver transplant.
- The genetically engineered porcine liver used in this study carried the same genetics as the porcine kidneys used in the landmark preclinical study recently published in Nature .
Retrieved on:
Thursday, October 26, 2023
Massachusetts General Hospital,
Survival,
RNA,
Antigen,
CRISPR,
Cell Transplantation,
Organ dysfunction,
Kidney,
Cell,
Pelvic floor dysfunction,
Transgene,
System,
Organ transplantation,
Risk,
Congress,
Complement,
Gene,
Endothelium,
Transplant,
Patient,
NHP,
Ischemia,
Pharmaceutical industry,
Dentistry,
Vaccine,
Nature Two presentations will highlight data from the company’s landmark preclinical proof of concept study for kidney transplant recently published in Nature.
Key Points:
- Two presentations will highlight data from the company’s landmark preclinical proof of concept study for kidney transplant recently published in Nature.
- A third presentation will share the results of a study evaluating pancreatic islets from genetically engineered porcine donors transplanted into a mouse model.
- “We’re thrilled to share data highlighting our lead candidate for kidney transplant, EGEN-2784, as well as additional data supporting our genome engineering platform.
- Humanized porcine donors were genetically engineered using the Yucatan miniature pig breed to carry 69 genomic edits through CRISPR/Cas 9 technology.
Retrieved on:
Wednesday, October 11, 2023
Xenotransplantation,
Engineering,
Biomarker,
Hope,
Inflammation,
Genome,
Endothelium,
Risk,
Data,
Massachusetts General Hospital,
Survival,
Coagulation,
Transplant,
Hospital,
Patient,
Organ dysfunction,
Pelvic floor dysfunction,
Gene,
Harvard Medical School,
Transgene,
NHP,
Human,
Filtration,
Vaccine,
Dentistry,
Nature CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible (HuCo™) organs for the treatment of organ failure, today announced publication in the journal Nature of long-term survival data from a proof-of-concept study evaluating engineered porcine donor kidneys transplanted into a cynomolgus macaque model. This dataset will support advancement of the company’s lead candidate for kidney transplant, EGEN-2784, toward clinical development.
Key Points:
- These results represent the largest and most comprehensive preclinical dataset published in the field to date.
- Recipient survival in the preclinical setting has historically been measured in weeks or months.
- The publication titled: “ Design and Testing of a Humanized Porcine Donor for Xenotransplantation ,” reported long-term survival of NHP recipients of the company’s genetically engineered porcine kidneys.
- “At eGenesis, we are focused on transformational progress for the field – improving long-term survival for transplant recipients from months to years,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis.
RAAS,
PTH,
Biotechnology,
Transplant,
Gene editing,
Survival,
Nature Communications,
NHP,
Chronic kidney disease,
Hypophosphatemia,
Hypercalcaemia,
Risk,
Pelvic floor dysfunction,
Pharmaceutical industry,
Vaccine “Taken together, our collective findings provide additional evidence demonstrating the ability of the xenotransplanted kidneys to carry out normal physiological function over extended periods,” said Katherine Hall, Ph.D., Principal Scientist of eGenesis.
Key Points:
- “Taken together, our collective findings provide additional evidence demonstrating the ability of the xenotransplanted kidneys to carry out normal physiological function over extended periods,” said Katherine Hall, Ph.D., Principal Scientist of eGenesis.
- “They also inform areas for monitoring and potential pharmaceutical intervention in the first-in-human clinical setting for renal xenotransplantation.
- Chronic kidney disease affects between 8 and 16 percent of the population worldwide, and demand for donor kidneys far outpaces supply.
- One approach to alleviating this global issue is xenotransplantation, or the transplantation of organs from one species to another.
Xenotransplantation,
Thrombotic microangiopathy,
Tissue,
Survivor,
TGS,
ATI,
DNA,
Immunology,
Serum,
Biotechnology,
Gene editing,
Survival,
AMR,
Cell,
Antibody,
Doctor of Philosophy,
TG,
Research,
DSA,
Harvard Medical School,
Transplant,
Chemistry,
Sera,
Protein,
Public,
Animal,
MD,
Plasma,
Risk,
Coagulation,
Filtration,
Hospital,
ATC,
Hokkaido University,
SLA,
Health,
Safety,
Pelvic floor dysfunction,
Postdoctoral researcher,
TMA,
Medical device,
Dentistry,
Vaccine,
Dietary supplement,
Primate CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American Transplant Congress (ATC) 2023, held June 3 – June 7, 2023 in San Diego, CA.
Key Points:
- CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American Transplant Congress (ATC) 2023, held June 3 – June 7, 2023 in San Diego, CA.
- “The data we are presenting at ATC 2023 demonstrate eGenesis’ continued leadership in the field of xenotransplantation,” said Mike Curtis, Ph.D., CEO of eGenesis.
- Oral Presentation: Genetically Modified Porcine Kidneys Expressing Human Transgenes Support >2-year Survival in Porcine Donor to Cynomolgus Macaque Recipient Xenotransplantation.
- eGenesis scientists genetically engineered porcine donors to remove three known xenoantigens implicated in hyperacute rejection.
Infection,
DNA,
Human,
Partnership,
Biotechnology,
Liquid biopsy,
Cell,
Transplant,
M.D,
Patient,
Risk,
Primate,
The New England Journal of Medicine,
Diagnosis,
AI,
Safety,
Pelvic floor dysfunction,
Genome,
Vaccine,
Medicine,
Loris Karius,
Xenotransplantation REDWOOD CITY, Calif. and CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- Karius®, the world leader in liquid biopsy for infectious diseases, and eGenesis, Inc. a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced a partnership through which the two companies will develop infectious disease diagnostics for xenotransplantation initially from porcine to primates and ultimately to humans. Through the partnership, Karius will leverage its platform to power the detection and quantification of pathogens with potential to occur in porcine organ donors.
Key Points:
- Through the partnership, Karius will leverage its platform to power the detection and quantification of pathogens with potential to occur in porcine organ donors.
- Karius and eGenesis will collaborate in the development of this expanded platform and plan to complete this work by early 2024.
- An estimated 6,000 of these patients will die each year before they receive an organ transplant1.
- "The expansion into infectious disease diagnostics in xenotransplantation provides another proof point for our platform's plasticity through data and AI."
Retrieved on:
Tuesday, January 24, 2023
Cell,
Mustang,
Molecular biology,
Regenerative medicine,
Biotechnology,
CMC,
Hospital,
Biogen,
Organ transplantation,
Manifest and latent functions and dysfunctions,
Humboldt University of Berlin,
Patient,
Cell therapy,
Dana–Farber Cancer Institute,
University of Göttingen,
Doctor of Philosophy,
Merck Millipore,
Pharmaceutical industry,
Operation,
Biology,
Pfizer CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.
Key Points:
- CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.
- “We are pleased to welcome Knut to the team and are confident he will help us advance our goal of transforming the treatment paradigm for organ failure,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis.
- “Synthetic biology and gene engineering are core components of our approach to developing high-quality, transplantable organs that ultimately save lives.
- “Powered by a strong technological platform, eGenesis is well-positioned to address the hurdles that have hindered the field of xenotransplantation to date,” Dr. Niss said.
IND,
Cell,
CD154,
Kidney,
Heart,
Manifest and latent functions and dysfunctions,
Immunomodulation,
Immunosuppression,
FDA,
Drug development,
Immune system,
Patient,
CD40,
Immunoglobulin G,
CD40L,
Pharmaceutical industry,
Eledone CAMBRIDGE, Mass. and IRVINE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- eGenesis, Inc. (“eGenesis”) and Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that they have entered into a collaborative research agreement under which eGenesis will gain access to Eledon’s anti-CD40L antibody candidate, tegoprubart, for eGenesis’ ongoing preclinical research and development studies of human-compatible organs and cells for the treatment of organ failure. The collaboration has the potential to span multiple eGenesis programs including kidney, heart and islet cell transplant.
Key Points:
- -Agreement leverages Eledon’s investigational anti-CD40L antibody, tegoprubart, as part of eGenesis’ immunosuppression regimen that prevents xenotransplant rejection in nonhuman primate recipients-
-Establishes framework for use of tegoprubart for preclinical xenotransplantation studies in support of eGenesis’ kidney, heart and islet cell programs-
CAMBRIDGE, Mass.
- and IRVINE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- eGenesis, Inc. (“eGenesis”) and Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that they have entered into a collaborative research agreement under which eGenesis will gain access to Eledon’s anti-CD40L antibody candidate, tegoprubart, for eGenesis’ ongoing preclinical research and development studies of human-compatible organs and cells for the treatment of organ failure.
- The collaboration has the potential to span multiple eGenesis programs including kidney, heart and islet cell transplant.
- “Despite significant recent progress and momentum in the field of xenotransplantation, improving organ compatibility to prevent rejection remains an ongoing challenge,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis.
